Uridine phosphorylase (UPase) has been shown to play an important role in the antineoplastic activity of 5-fluorouracil (5-FU) and in the anabolism of its oral prodrug, capecitabine, through the conversion of 5Ј-deoxy-5-fluorouridine (5Ј-DFUR) into 5-FU. In this study, we investigated the effect of tumor necrosis factor-␣ (TNF-␣) on UPase gene expression and 5Ј-DFUR antiproliferative activity and elucidated the involved signal transduction pathway. Our data indicate that TNF-␣ significantly induced UPase mRNA expression and its enzymatic activity in EMT6 murine breast cancer cells, leading to an enhanced cytotoxicity of 5Ј-DFUR. This is further confirmed by an increased incorporation of 5Ј-DFUR-originated 5-FU nucleotides into nucleic acids. To clarify the mechanism of TNF-␣-induced UPase expression, we first observed the effect of
TNF-␣ on the UPase promoter activity with a series of 5Ј-deleted promoter-luciferase constructs. Transient transfection analysis showed that the TNF-␣-inductive pattern in EMT6 cells was consistent with the presence of a nuclear factor-B (NF-B) binding element (Ϫ1332/Ϫ1312 bp) in the UPase promoter region. Furthermore, electrophoretic mobility shift assays, supershift, and cotransfection assays revealed that the activation of p65 was responsible for UPase induction by TNF-␣. Finally, the induction of UPase by TNF-␣ could be suppressed by PS-341, a NF-B inhibitor. In summary, TNF-␣ efficiently induces UPase gene expression through a NF-B subunit p65-dependent pathway enhancing cell sensitivity to 5Ј-DFUR. The elucidation of this regulation mechanism may aid in the clinical use of 5-FU-based chemotherapy.
Uridine phosphorylase (UPase), which can reversibly convert uridine to uracil, plays a crucial role in the activation of fluoropyrimidines such as 5-fluorouracil (5-FU), its prodrug 5Ј-deoxy-5-flurouridine (5Ј-DFUR), and in "the uridine rescue" of normal tissues Cao and Pizzorno, 2004) . Our previous studies have shown that the abrogation of UPase activity in murine embryonic stem cells significantly reduced the cell sensitivity to 5-FU, 5Ј-DFUR, and phosphonacetyl-L-aspartic acid compared with wild-type embryonic stem cells . In UPase Ϫ/Ϫ mice, the loss of UPase activity resulted in greater increase in uridine levels in plasma and tissues, reduction of 5-fluorouracil host toxicity, and alteration of the anesthetic effect of pentobarbital (Cao et al., 2005) . Compared with adjacent normal tissues, UPase activity has been shown to be elevated in various human solid tumors, including breast carcinomas (Liu et al., 1998; Kanzaki et al., 2002) , colorectal carcinomas (Katsumata et al., 2003) , oral squamous carcinomas (Maehara et al., 1990; Miyashita et al., 2002) , melanoma tissue (Leyva et al., 1983) , and lung adenocarcinomas (Maehara et al., 1990) , providing a rationale for targeting this enzyme for tumor-specific modulation of fluoropyrimidines activity. Very little is currently known about the regulatory mechanisms of UPase gene expression. Some investigators have indicated that cytokines such as tumor necrosis factor-alpha (TNF-␣), interleukin-1␣ (IL-1␣), and interferon-␣ and -␥ (IFN-␣ and -␥) can induce UPase gene expression with consequent improvement of 5-FU and 5Ј-DFUR antiproliferative activity (Eda et al., 1993) , but the molecular regulatory mechanism has not been described extensively.
Uridine has been used as a biochemical modulator to reduce 5-FU host toxicity and escalate 5-FU dosage to improve the therapeutic index of this pyrimidine antimetabolite (Peters, 1988; Martin et al., 1989; Seiter et al., 1993) . This has been based on the hypothesis that the host toxicity of 5-FU is mainly related to RNA dysfunction caused by 5-FU incorporation, whereas its antitumor activity is ascribed to thymidylate synthase inhibition and resultant DNA damages (Kufe and Major, 1981; Major et al., 1982; Longley et al., 2003) . Unfortunately, this potentially useful clinical practice has been limited by the dose-related toxicities of uridine, because the administration of large doses of the pyrimidine nucleoside are required to maintain therapeutic plasma uridine concentration because of its rapid clearance catalyzed by UPase. In this study, we confirmed the induction of UPase gene expression by TNF-␣, elucidated the regulatory mechanisms, and evaluated the effect of UPase modulation on 5Ј-DFUR antiproliferative activity, an intermediate in the enzymatic activation of capecitabine, an oral prodrug of 5-FU recently approved by the FDA for the treatment of advanced breast and colon cancers (Miwa at al., 1998; Blum, 1999; Hoff et al., 2001; Van Cutsem et al., 2001 ).
Materials and Methods
Reagents and Antibodies. Bacteria-derived mouse recombinant TNF-␣ with a specific activity of Ͼ1 ϫ 10 7 U/mg, IL-1␣ with a specific activity of Ͼ5 ϫ 10 9 U/mg, and IFN-␥ with a specific activity of Ͼ1 ϫ 10 7 U/mg were purchased from Chemicon, Inc. (Temecula, CA). The following polyclonal or monoclonal antibodies were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA): anti-p65, anti-p50, and anti-c-Rel. IB inhibitor PS-341 is a product of Millennium Pharmaceuticals (Cambridge, MA). 5Ј-DFUR was purchased from Sigma-Aldrich (St. Louis, MO) and dissolved in water at a stock concentration of 50 mM. Cells and Culture Conditions. EMT6 cells, a murine breast cancer cell line (kindly provided by Dr. Sarah Rockwell, Yale University, New Haven, CT), were maintained in Waymouth's MB 752/1 medium (Invitrogen, Carlsbad, CA) with 15% fetal bovine serum, 100 U/ml penicillin, and 100 U/ml streptomycin (Sigma) at 37°C in humidified atmosphere of 5% CO 2 /95% air.
Northern Blot Hybridization. Total RNA was extracted with TRIzol reagents (Invitrogen, Carlsbad, CA). Total RNA, 15 g/lane, was electrophoretically separated on a 1.2% formaldehyde-agarose gel, blotted to Hybond-N ϩ nylon membranes (GE Healthcare, Little Chalfont, Buckinghamshire, UK), and fixed at 80°C for 2 h. The membranes were subsequently hybridized with 32 P-labeled mouse UPase cDNA and ␤-actin cDNA probes (Ambion, Austin, TX) in an ULTRAhyb ultrasensitive hybridization buffer (Ambion) for 18 h, washed, and exposed to X-ray films at Ϫ70°C. Bands in the autoradiogram were quantitated by means of filmless autoradiographic analysis. The UPase levels were normalized to that of ␤-actin levels in each lane to correct for the amount of total RNA loaded.
UPase Enzymatic Activity Assay. UPase enzymatic activity was measured by the conversion of the natural substrate uridine to uracil using thin-layer chromatographic separation. At the same time, activities of thymidine phosphorylase (TPase), orotate phosphoribosyl transferase, and uridine kinase were analyzed as described previously .
In Vitro Cytoxicity Assay. The antiproliferative activity of 5Ј-DFUR was assessed by cell proliferation kit II [sodium 3Ј-[1-phenylaminocarbonyl]-3, 4-tetrazolium)-bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate]. In brief, 1000 EMT6 cells/well were plated in 96-well tissue culture plates. The following day, the cells were pretreated with 20 ng/ml TNF-␣ for 24 h (inducing UPase expression) followed by the addition of different concentrations of 5Ј-DFUR to the medium for an additional 72 h. Each concentration point was replicated in eight wells, and all experiments were conducted minimally in triplicate.
Incorporation of [ 3 H]5-DFUR into Nucleic Acids. Cells (1 ϫ 10 5 /well) were plated in six-well plates. After overnight incubation, the cells were pretreated with 20 ng/ml TNF-␣ for 24 h, followed by the addition of 30 or 100 M 5Ј-DFUR with 5 Ci/well of [ 3 H]5Ј-DFUR for an additional 4 h. DNA and total RNA were extracted at the end of the treatment with TRIzol reagents (Invitrogen) according to the manufacturer's instructions. Purified RNA and DNA were dissolved in 400 l of distilled water, respectively. The amount of incorporated 5Ј-DFUR anabolites (pmol/10 6 cells) was calculated after determining the specific activity 5Ј-DFUR relative to each experiment.
Transfection and Luciferase Assays. The transfection was conducted in triplicate in six-well plates. Approximately 10 5 cells/ well were seeded for 24 h before transfection. Two micrograms of supercoiled plasmid DNA (5Ј-deleted mouse UPase promoter constructs, p65/pc-DNA-3, p50/pc-DNA-3, and c-rel/pc-DNA-3) and an internal control (pRL-TK plasmid) were cotransferred into cells using LipofectAMINE reagent (Invitrogen). Vector-alone transfected cells were used as a negative control. The cells were incubated in transfection buffer (serum-free medium) for 3 h and then incubated in Waymouth's medium with 15% fetal bovine serum. After 24 h, the cells were treated with or without 20 ng/ml TNF-␣ for an additional 24 h. Firefly luciferase and the control Renilla reniformis luciferase were detected using a dual luciferase detection kit (Luciferase Assay System; Promega, Madison, WI).
Electrophoretic Mobility Shift Assay. Nuclear extracts were prepared as described previously in detail (Lin et al., 1998) . Electrophoretic mobility shift assay (EMSA) was conducted according to a modified protocol provided by the manufacturer (Promega). Doublestranded DNA probes containing the NF-B element located at Ϫ1339 to Ϫ1320 bp of the UPase promoter [5Ј-CATTTTTGGGTTT-TCCCTTC-3Ј (potential binding region is in bold)] and the c-Rel element located at Ϫ71 to Ϫ58 bp (5Ј-AGGAAGGACCCTGA-3Ј) were synthesized by the Oligonucleotide Synthesis Facility of the Department of Pathology of the Yale University School of Medicine. Consensus NF-B oligonucleotides were provided by the manufacturer (Promega). For binding specificity determination, a 100-fold excess of unlabeled or mutant NF-B and c-Rel oligonucleotides was added as specific or nonspecific probes in the binding reaction. For the supershift assays, nuclear extracts were incubated with antibodies against p50, c-Rel, or p65 of NF-B for 45 min on ice before the labeled probes were added. The reaction products were separated onto a 6% nondenaturing polyacrylamide gel and visualized by autoradiography.
Statistical Analysis. Data shown in the figures and tables are reported as the mean Ϯ S.D. of at least three experiments. Differences between groups were compared using the Student's t test. Differences resulting in P values Ͻ0.05 were considered to be statistically significant.
Results

Induction by TNF-␣ of UPase Gene Expression in
Murine Breast Tumor Cells. Watanabe et al. (1995) reported that the expression of the UPase gene was elevated in various human cancer cell lines by a combination of the three cytokines, TNF-␣, IL-1␣, and IFN-␥, and vitamin D 3 . To investigate the molecular mechanism, we initially treated mouse mammary EMT6 cells with individual cytokines, in- cluding TNF-␣, IL-1␣, or IFN-␥ alone. UPase mRNA expression and enzymatic activity were determined to estimate the inductive efficiency of each cytokine. As shown in Fig. 1, A and B, TNF-␣ (20 ng/ml) caused a significant increase of UPase mRNA level, with consequent elevated enzymatic activity, IFN-␥ alone induced a significant but variable increase of UPase gene products, and IL-1␣ produced only a minimal change in UPase expression. The concurrent increase in both UPase mRNA and enzyme activity indicates that TNF-␣ stimulates UPase activity at the transcriptional level. Analysis with different concentrations of TNF-␣ revealed that the UPase stimulation by TNF-␣ was dose-dependent, with maximal induction at 40 ng/ml (Fig. 1C) . However, the death of EMT6 cells exposed to TNF-␣ was also dose-dependent. We observed that the majority of the cultured cells would die in medium containing 40 ng/ml of TNF-␣ alone during 72 h of exposure. Therefore, we decided to choose 20 ng/ml as the standard concentration of TNF-␣ for all our studies because it caused only minimal cell death. The activity levels of the other enzymes involved in the metabolism and activation of 5-FU, including TPase, uridine kinase, and orotate phosphoribosyl transferase, were at or below the limit of detection and were not affected when the cells were treated with individual cytokines (data not shown).
Enhanced Sensitivity to 5-DFUR of EMT6 Cells Treated with TNF-␣. Capecitabine has no antiproliferative activity on its own before its activation in the liver to 5Ј-DFUR and subsequent metabolism to 5-FU by pyrimidine nucleoside phosphorylases, UPase, and TPase (Ishitsuka et al., 1980; Armstrong et al., 1983 ). Therefore, we tested directly the effect of cytokines on the antiproliferative activity of 5Ј-DFUR in EMT6 cells. After pretreatment with TNF-␣ (20 ng/ml) for 24 h (induction of UPase expression), the sensitivity of EMT-6 cells to 5Ј-DFUR significantly increased by 2.5-fold with the IC 50 value that decreased from 25 to 10 M (Fig. 2) . This difference in sensitivity was consistent with an increased incorporation of 5Ј-DFUR anabolites into RNA and DNA (Table 1 ) compared with nontreated EMT6 cells using both 30 and 100 M concentrations of the fluorinated antimetabolite. However, when the cells were simultaneously exposed to 5Ј-DFUR and the specific UPase inhibitor BAU (50 M), the increased sensitivity and incorporation of 5Ј-DFUR anabolites were abolished, indicating that the increased antiproliferative activity is directly associated with the induction of UPase by TNF-␣.
Identification of Functional NF-B Binding Site in UPase Promoter. To understand the molecular mechanism of TNF-␣-induced UPase gene expression, we performed a motif analysis of the UPase promoter. The results indicated the presence of two NF-B putative binding elements, sequence 5Ј-GGGTTTTCC-3Ј at Ϫ1332 to Ϫ1323 bp and 5Ј-GGGTCCTTCC-3Ј at Ϫ70 to Ϫ62 bp. To test the functionality of these elements, we first observed the relationship between the kinetics of NF-B activation (indicated by EMSA) and UPase induction by TNF-␣. As shown in Fig. 3A , TNF-␣ treatment resulted in a biphasic NF-B activation in EMT6 cells with a rapid activation of NF-B occurring within 15 min and a maximum peak at 30 min, as reported previously in other cell types (Han and Brasier, 1997; Hoffmann et al., 2002) . The second peak of NF-B activity took place between 8 and 12 h from the initial exposure to TNF-␣. The enzymatic 
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at ASPET Journals on June 21, 2017 molpharm.aspetjournals.org activity of UPase followed a similar biphasic pattern with a rapid induction within 15 min after exposure to TNF-␣ that reached a maximum peak of activity at 30 min, indicating the relationship between NF-B activation and UPase induction. The elevated UPase activity was sustained for 24 h (Fig. 3B) , possibly because of the longer half-life of the UPase protein.
To further clarify the role of NF-B in UPase induction by TNF-␣, several deleted UPase promoter-luciferase constructs containing or not NF-B binding sites (Fig. 4, left) were transfected into EMT6 cells. As shown in Fig. 4 (right) , exposure to TNF-␣ caused a 1.8-fold increase in luciferase activity in the p-1619 construct, which contains both of the putative NF-B binding sites. Removal of one of the putative NF-B binding sites at Ϫ1332 to Ϫ1323 bp (p-1081 construct) led to a significant reduction of both basal and TNF-␣-induced UPase promoter activity, whereas a further deletion to Ϫ84 bp (p-84 construct) almost completely abolished these effects. These results indicated that the NF-B binding site at Ϫ1332 to Ϫ1323 bp of the murine UPase promoter is functionally responsible for the TNF-␣-induced UPase expression, not the putative site at Ϫ70 to Ϫ62 bp.
NF-B Regulates UPase Expression via DNA Sequence Specific Binding. To elucidate the regulatory mechanism of NF-B on UPase expression, we performed EMSA using double-stranded, synthetic oligonucleotide probes representative of the putative NF-B elements at Ϫ1332 to Ϫ1323 bp and Ϫ70 to Ϫ62 bp, respectively. As displayed in Fig. 5A , the nuclear proteins extracted from TNF-␣-treated EMT6 cells specifically bound the oligonucleotide probe corresponding to Ϫ1332 to Ϫ1323 bp, and the binding ability was positively related to TNF-␣ concentrations (Fig. 5B) . A 100-fold excess of unlabeled NF-B probes completely abolished the formation of this complex (Fig. 5A) , indicating the NF-B specificity of this complex. To further confirm the specificity of the DNA protein complexes and identify the active subunit in the NF-B complex, we performed a supershift assay with specific antibodies against p65, p50, and c-Rel. Preincubations of nuclear extracts with these antibodies indicated that the presence of the p65 antibody, not p50 or c-Rel antibodies, retarded the mobility of the specific complex (Fig. 5B) . These data suggest that the NF-B p65 was the subunit responsible for TNF-␣ regulation of UPase expression at the promoter level. No specific complexes were formed with oligonucleotide corresponding to the element located at Ϫ70 to Ϫ62 bp (data not shown).
The Effect of PS-341 and p65 Gene Cotransfection on UPase Promoter Activity. The specificity of NF-B p65 regulation on TNF-␣-induced UPase expression was further confirmed by investigating the effect of the NF-B inhibitor PS-341 (Sunwoo et al., 2001 ) and p65 gene cotransfection on UPase activity. As expected, the block of NF-B function by bortezomib (PS-341) resulted in the inhibition of UPase mRNA expression and UPase enzymatic activity in a concentration-dependent fashion (Fig. 6, A and B) . In addition, we also cotransfected the UPase promoter construct p-1619 containing the putative NF-B binding site at Ϫ1332 to Ϫ1323 bp or p-1081 without this NF-B binding site with p50, p65, and c-Rel expression vectors into EMT6 cells, respectively. As shown in Fig. 7 , the introduction of p65 greatly stimulated the UPase promoter activity, but p50 and c-Rel did not. It is more interesting that PS-341 could also efficiently inhibit the p-1619 construct activity induced by either p65 transfection or TNF-␣ addition. Neither cotransfection with p65, p50, and c-Rel nor TNF-␣ exposure significantly affected the activity of the construct p-1081 lacking the NF-B binding site at Ϫ1332 to Ϫ1323 bp.
Discussion
The murine UPase promoter region contains several putative regulatory elements for cytokine-induced transcriptional factors, oncogenes, and tumor suppressor gene factors (i.e., p53) (Cao et al., 1999) . Because of the lack of canonical TATA or CAAT box in the UPase promoter, the presence of these transcriptional regulatory elements may contribute to the initiation of UPase transcription. We have elucidated previously the regulatory mechanism of the tumor suppressor gene p53 on UPase gene expression, in which p53 represses UPase gene expression by specifically binding to a p53 consensus site at Ϫ303 and Ϫ294 bp in the UPase promoter (Zhang et al., 2001 ). This has provided an explanation for the critical role of p53 regulation of pyrimidine nucleotide pools. In the current study, we examined the influence of TNF-␣ on UPase expression in EMT6 cells and the resultant effect on 5Ј-DFUR antiproliferative activity. Furthermore, we elucidated the regulatory mechanism of TNF-␣ on UPase expression.
Motif analysis of the UPase promoter region indicated the presence of two NF-B binding sites located at Ϫ1332 to Ϫ1323 bp and Ϫ70 to Ϫ62 bp, respectively, of the UPase promoter region. To evaluate their functional status and possible involvement in TNF-␣-induced UPase gene expression, we conducted a promoter activity assay with a series of deleted UPase promoter-luciferase constructs. The results indicated that the presence of the NF-B binding element at Ϫ1332 to Ϫ1323 bp conferred the TNF-␣ inducibility of the UPase promoter. The EMSA assays further confirmed this finding. The sequence at Ϫ1332 to Ϫ1323 bp displayed a specific binding with nuclear proteins prepared from EMT6 cells, and this binding activity was positively related to the TNF-␣ treatment. The element at Ϫ70 to Ϫ62 bp showed no binding activity. These data suggest that TNF-␣ may induce UPase expression first via the activation of the NF-B pathway, which later stimulates UPase expression through DNA sequence-specific binding to the element at Ϫ1332 to Ϫ1323 bp.
The NF-B family includes five distinct subunits: NF-B1 (p50/p105), NF-B2 (p52/p100), RelA (p65), RelB, and c-Rel. The NF-B subunits can undergo either homo-or heterodimerization in the cytoplasm before activation, but the p50/p65 heterodimer is the predominant one. Upon stimulation, either of the subunits moves into the nuclei and activates the effectors' gene expression (Leong and Karsan, 2000) . To identify the subunit(s) involved in UPase gene expression, we performed supershift assays with specific antibodies against p65, p50, and c-Rel. The results indicated that only the presence of the anti-p65 antibody caused the retardation of shift bands, indicating that it is the NF-B subunit p65 that contributes to the TNF-␣-induced UPase expression. This is further confirmed by p65 gene cotransfection with the UPase promoter-luciferase constructs containing the Ϫ1332 to Ϫ1323 bp element (p-1619), which led to a significant elevation of luciferase activity. However, p65 expression had no effect on the UPase promoter activity in the construct without the Ϫ1332 to Ϫ1323 bp element (p-1081). In addition, we also observed the effect of an NF-B inhibitor, PS-341, on endogenous UPase expression and UPase promoter-luciferase construct activity in response to TNF-␣ stimulation. As expected, PS-341 efficiently inhibited TNF-␣-induced endogenous UPase gene expression and UPase promoter activity. Taken together, our data suggest that TNF-␣ induces UPase gene expression via the activation of NF-B subunit p65 and subsequent binding to the element located at Ϫ1332 to Ϫ1323 bp in the murine UPase promoter.
Fluoropyrimidines are a group of antimetabolite agents widely used in the treatment of breast, gastrointestinal, and head/neck tumors; however, their clinical success has been limited by serious host toxicity because of their poor tumor selectivity. Over the years, a major effort has been dedicated to the tumor-specific modulation of their action. Capecitabine is an oral agent designed to generate 5-FU preferentially in tumor tissues (Schilsky, 2000) . The tumor selectivity of capecitabine has been confirmed in both tumor xenografts and human colon carcinoma tissues (Schü ller et al., 2000) . Schü ller et al. found that the concentration of 5-FU in primary colorectal tumors was, on average, 3.2 times higher than in adjacent healthy tissue and 21.4-fold higher than that in plasma. 5Ј-DFUR, an intermediate metabolite, is the critical step that provides tumor specificity to capecitabine through its conversion to 5-FU catalyzed by pyrimidine phosphorylases UPase and TPase. It has been well documented that both UPase and TPase are both induced in tumor tissues (Leyva et al., 1983; Maehara et al., 1990; Saeki et al., 1997; Liu et al., 1998; Kanzaki et al., 2002; Miyashita et al., 2002; Yang et al., 2002; Katsumata et al., 2003; Shimabukuro et al., 2005) . Whereas the regulatory mechanism of UPase expression was still unclear, the mechanism of TPase regulation has been reported previously. Several studies have indicated that TPase expression is stimulated by TNF-␣ (Goto et al., 2001; Zhu et al., 2002) . In our study using the EMT6 model, we found that the basal activity of TPase in these cells is barely detectable, and the TNF-␣ treatment has no effect on its activity level, indicating that TPase expression is not TNF-␣-inducible in this cell line. Therefore, the increased 5Ј-DFUR toxicity in EMT6 cells by TNF-␣ has to be entirely ascribed to the induction of UPase.
In summary, this study not only provides direct evidence for the role of UPase in the activation of fluoropyrimidines in general and more specifically of 5Ј-DFUR but also elucidates the mechanism leading to the elevated expression of the pyrimidine enzyme after TNF-␣ stimulation. This study also provides the first direct evidence of TNF-␣ involvement in the regulation of fluoropyrimidine-activating enzymes and warrants a systematic evaluation of the expression of TNF-␣ and pyrimidine phosphorylases in tumors to properly design a therapeutic approach that exploits the tumor-selective activation of these fluorinated antimetabolites.
